Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Pexidartinib | hsa00030 | Pentose phosphate pathway | 1.08E-05 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | Pexidartinib | hsa00040 | Pentose and glucuronate interconversions | 3.53E-02 | 1 | O60701 | UGDH | More | | Pexidartinib | hsa00051 | Fructose and mannose metabolism | 3.92E-03 | 3 | P15121, P19367, P08237 | AKR1B1, HK1, PFKM | More | | Pexidartinib | hsa00052 | Galactose metabolism | 3.77E-04 | 5 | P06280, P08237, O43451, P15121, P19367 | GLA, PFKM, MGAM, AKR1B1, HK1 | More | | Pexidartinib | hsa00190 | Oxidative phosphorylation | 4.38E-04 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | Pexidartinib | hsa00220 | Arginine biosynthesis | 5.61E-05 | 3 | P15104, P05089, P49448 | GLUL, ARG1, GLUD2 | More | | Pexidartinib | hsa00230 | Purine metabolism | 4.93E-02 | 1 | P21589 | NT5E | More | | Pexidartinib | hsa00240 | Pyrimidine metabolism | 1.81E-02 | 1 | P21589 | NT5E | More | | Pexidartinib | hsa00310 | Lysine degradation | 2.60E-03 | 3 | Q8NEZ4, Q13029, Q02809 | MLL3, PRDM2, PLOD1 | More | | Pexidartinib | hsa00500 | Starch and sucrose metabolism | 1.91E-04 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Pexidartinib | hsa00520 | Amino sugar and nucleotide sugar metabolism | 7.84E-04 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | | Pexidartinib | hsa00563 | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 3.01E-02 | 1 | Q14442 | PIGH | More | | Pexidartinib | hsa00564 | Glycerophospholipid metabolism | 3.56E-02 | 3 | P48651, Q9Y6K0, P35790 | PTDSS1, CEPT1, CHKA | More | | Pexidartinib | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Pexidartinib | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Pexidartinib | hsa00603 | Glycosphingolipid biosynthesis - globo and isoglobo series | 7.02E-03 | 2 | P06865, O75752 | HEXA, B3GALNT1 | More | | Pexidartinib | hsa00640 | Propanoate metabolism | 3.83E-02 | 2 | Q02252, Q9P2R7 | ALDH6A1, SUCLA2 | More | | Pexidartinib | hsa00670 | One carbon pool by folate | 1.33E-02 | 2 | P04818, Q99707 | TYMS, MTR | More | | Pexidartinib | hsa00730 | Thiamine metabolism | 1.55E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Pexidartinib | hsa00740 | Riboflavin metabolism | 4.77E-02 | 1 | P30043 | BLVRB | More | | Pexidartinib | hsa00760 | Nicotinate and nicotinamide metabolism | 9.09E-03 | 1 | P21589 | NT5E | More | | Pexidartinib | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | Pexidartinib | hsa00830 | Retinol metabolism | 3.93E-02 | 3 | P00352, Q9BPW9, O75911 | ALDH1A1, DHRS9, DHRS3 | More | | Pexidartinib | hsa00860 | Porphyrin and chlorophyll metabolism | 1.66E-03 | 3 | P36551, P53004, P30043 | CPOX, BLVRA, BLVRB | More | | Pexidartinib | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Pexidartinib | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Pexidartinib | hsa01100 | Metabolic pathways | 2.92E-03 | 39 | Q9NR34, Q9Y234, P35790, P05089, Q16772, P30041, P19367, P48426, P22557, P32320, P20839, P22748, P55809, P06280, Q16875, O43286, O43451, Q9Y6K0, P05186, P24666, P15121, P08237, O95861, Q9HCC0, P33121, Q86VZ5, P48651, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737, Q969G6, P14927 | MAN1C1, LIPT1, CHKA, ARG1, GSTA3, PRDX6, HK1, PIP4K2A, ALAS2, CDA, IMPDH1, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, CEPT1, ALPL, ACP1, AKR1B1, PFKM, BPNT1, MCCC2, ACSL1, SGMS1, PTDSS1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL, RFK, UQCRB | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q9NR34 | MAN1C1 | Mannosyl-oligosaccharide 1,2-alpha-mannosidase IC | -0.716 | P19784 | CSNK2A2 | Casein kinase II subunit alpha' | Q9Y234 | LIPT1 | Lipoyltransferase 1, mitochondrial | 0.829 | P19784 | CSNK2A2 | Casein kinase II subunit alpha' | P35790 | CHKA | Choline kinase alpha | -0.778 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P05089 | ARG1 | Arginase-1 | 0.702 | P19784 | CSNK2A2 | Casein kinase II subunit alpha' | Q16772 | GSTA3 | Glutathione S-transferase A3 | -0.791 | P19784 | CSNK2A2 | Casein kinase II subunit alpha' | P30041 | PRDX6 | Peroxiredoxin-6 | 0.893 | P19784 | CSNK2A2 | Casein kinase II subunit alpha' | P19367 | HK1 | Hexokinase-1 | 0.777 | P19784 | CSNK2A2 | Casein kinase II subunit alpha' | P48426 | PIP4K2A | Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha | 0.745 | P19784 | CSNK2A2 | Casein kinase II subunit alpha' | P22557 | ALAS2 | 5-aminolevulinate synthase, erythroid-specific, mitochondrial | 0.707 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P32320 | CDA | Cytidine deaminase | 0.701 | P19784 | CSNK2A2 | Casein kinase II subunit alpha' | P20839 | IMPDH1 | Inosine-5'-monophosphate dehydrogenase 1 | 0.828 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P22748 | CA4 | Carbonic anhydrase 4 | 0.767 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P55809 | OXCT1 | Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial | -0.746 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P06280 | GLA | Alpha-galactosidase A | 0.714 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16875 | PFKFB3 | 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 | 0.849 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O43286 | B4GALT5 | Beta-1,4-galactosyltransferase 5 | 0.917 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O43451 | MGAM | Maltase-glucoamylase | 0.871 | P19784 | CSNK2A2 | Casein kinase II subunit alpha' | Q9Y6K0 | CEPT1 | Choline/ethanolaminephosphotransferase 1 | 0.802 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | 0.901 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P24666 | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | -0.832 | P19784 | CSNK2A2 | Casein kinase II subunit alpha' | P15121 | AKR1B1 | Aldo-keto reductase family 1 member B1 | 0.732 | P19784 | CSNK2A2 | Casein kinase II subunit alpha' | P08237 | PFKM | ATP-dependent 6-phosphofructokinase, muscle type | 0.82 | P19784 | CSNK2A2 | Casein kinase II subunit alpha' | O95861 | BPNT1 | 3'(2'),5'-bisphosphate nucleotidase 1 | -0.702 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q9HCC0 | MCCC2 | Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial | -0.782 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P33121 | ACSL1 | Long-chain-fatty-acid--CoA ligase 1 | 0.886 | P19784 | CSNK2A2 | Casein kinase II subunit alpha' | Q86VZ5 | SGMS1 | Phosphatidylcholine:ceramide cholinephosphotransferase 1 | -0.795 | P19784 | CSNK2A2 | Casein kinase II subunit alpha' | P48651 | PTDSS1 | Phosphatidylserine synthase 1 | 0.802 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P57054 | PIGP | Phosphatidylinositol N-acetylglucosaminyltransferase subunit P | -0.881 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q9UNP4 | ST3GAL5 | Lactosylceramide alpha-2,3-sialyltransferase | -0.819 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q9BX95 | SGPP1 | Sphingosine-1-phosphate phosphatase 1 | -0.743 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P32321 | DCTD | Deoxycytidylate deaminase | -0.748 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q9BPW9 | DHRS9 | Dehydrogenase/reductase SDR family member 9 | 0.817 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O75911 | DHRS3 | Short-chain dehydrogenase/reductase 3 | -0.81 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q9UHY7 | ENOPH1 | Enolase-phosphatase E1 | -0.737 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | 0.883 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P46976 | GYG1 | Glycogenin-1 | 0.817 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P06737 | PYGL | Glycogen phosphorylase, liver form | 0.863 | P19784 | CSNK2A2 | Casein kinase II subunit alpha' | Q969G6 | RFK | Riboflavin kinase | 0.797 | P19784 | CSNK2A2 | Casein kinase II subunit alpha' | P14927 | UQCRB | Cytochrome b-c1 complex subunit 7 | 0.721 |
| Pexidartinib | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | Pexidartinib | hsa01230 | Biosynthesis of amino acids | 2.22E-03 | 4 | P51854, P60891, Q99707, P37837 | TKTL1, PRPS1, MTR, TALDO1 | More | | Pexidartinib | hsa01240 | Biosynthesis of cofactors | 2.85E-04 | 7 | Q969G6, P13716, P36551, P22557, O60701, P14618, Q9Y234 | RFK, ALAD, CPOX, ALAS2, UGDH, PKM2, LIPT1 | More | | Pexidartinib | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P04049 | RAF1 | More | | Pexidartinib | hsa01522 | Endocrine resistance | 2.16E-02 | 1 | P04049 | RAF1 | More | | Pexidartinib | hsa01523 | Antifolate resistance | 1.68E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | | Pexidartinib | hsa01524 | Platinum drug resistance | 4.78E-02 | 1 | P31751 | AKT2 | More | | Pexidartinib | hsa02010 | ABC transporters | 1.08E-04 | 3 | P45844, P08183, Q8IZY2 | ABCG1, ABCB1, ABCA7 | More | | Pexidartinib | hsa03008 | Ribosome biogenesis in eukaryotes | 1.88E-02 | 3 | O14980, O60832, Q9BVP2 | XPO1, DKC1, GNL3 | More | | Pexidartinib | hsa03010 | Ribosome | 7.34E-03 | 6 | P62753, P62829, P62888, P61927, P61513, P36578 | RPS6, RPL23, RPL30, RPL37, RPL37A, RPL4 | More | | Pexidartinib | hsa03013 | RNA transport | 1.83E-08 | 20 | P62826, O14980, P52298, O14893, P61326, P38919, Q9UBU9, P37198, Q7Z3B4, P35658, P63279, P68104, Q14152, P55884, Q14240, Q9BZI7, P23588, Q9Y6A5, Q14232, Q06787 | RAN, XPO1, NCBP2, GEMIN2, MAGOH, EIF4A3, NXF1, NUP62, NUP54, NUP214, UBE2I, EEF1A1, EIF3A, EIF3B, EIF4A2, UPF3B, EIF4B, TACC3, EIF2B1, FMR1 | More | | Pexidartinib | hsa03015 | mRNA surveillance pathway | 4.81E-02 | 2 | Q9BZI7, O94913 | UPF3B, PCF11 | More | | Pexidartinib | hsa03020 | RNA polymerase | 5.39E-06 | 4 | P30876, P24928, P62487, Q9Y535 | POLR2B, POLR2A, POLR2G, POLR3H | More | | Pexidartinib | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | Pexidartinib | hsa03050 | Proteasome | 4.83E-02 | 1 | P55036 | PSMD4 | More | | Pexidartinib | hsa03320 | PPAR signaling pathway | 4.33E-02 | 2 | Q6PCB7, Q9UNU6 | SLC27A1, CYP8B1 | More | | Pexidartinib | hsa03460 | Fanconi anemia pathway | 2.71E-02 | 1 | O94782 | USP1 | More | | Pexidartinib | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P04049 | RAF1 | More | | Pexidartinib | hsa04012 | ErbB signaling pathway | 1.36E-03 | 5 | Q13153, P16333, P19174, P01106, P04049 | PAK1, NCK1, PLCG1, MYC, RAF1 | More | | Pexidartinib | hsa04014 | Ras signaling pathway | 4.31E-04 | 3 | P04049, P31751, P0DP23 | RAF1, AKT2, CALM1 | More | | Pexidartinib | hsa04015 | Rap1 signaling pathway | 2.83E-04 | 3 | P04049, P31751, P0DP23 | RAF1, AKT2, CALM1 | More | | Pexidartinib | hsa04020 | Calcium signaling pathway | 4.83E-02 | 4 | Q08828, P0DP23, P05141, P51828 | ADCY1, CALM1, SLC25A5, ADCY7 | More | | Pexidartinib | hsa04022 | cGMP-PKG signaling pathway | 6.51E-05 | 7 | P04049, P18848, P31751, Q08828, P51828, P05141, P0DP23 | RAF1, ATF4, AKT2, ADCY1, ADCY7, SLC25A5, CALM1 | More | | Pexidartinib | hsa04024 | cAMP signaling pathway | 1.08E-04 | 6 | Q08828, P51828, P31751, P0DP23, P04049, Q13153 | ADCY1, ADCY7, AKT2, CALM1, RAF1, PAK1 | More | | Pexidartinib | hsa04060 | Cytokine-cytokine receptor interaction | 8.46E-04 | 14 | P14784, P27930, P14778, P37173, P26842, Q06643, Q13651, P78552, P25024, Q9UBD3, P47992, P09341, P80075, P01730 | IL2RB, IL1R2, IL1R1, TGFBR2, CD27, LTB, IL10RA, IL13RA1, CXCR1, XCL2, XCL1, CXCL1, CCL8, CD4 | More | | Pexidartinib | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 1.83E-04 | 9 | Q8NHW4, P09341, P19875, P25024, P25025, P47992, Q9UBD3, Q13651, P14784 | CCL4L2, CXCL1, CXCL2, CXCR1, CXCR2, XCL1, XCL2, IL10RA, IL2RB | More | | Pexidartinib | hsa04062 | Chemokine signaling pathway | 1.90E-04 | 14 | P25024, P25025, P09341, P19875, P47992, Q9UBD3, P07948, P42338, P19174, P63218, P50151, P43250, Q08881, P04049 | CXCR1, CXCR2, CXCL1, CXCL2, XCL1, XCL2, LYN, PIK3CB, PLCG1, GNG5, GNG10, GRK6, ITK, RAF1 | More | | Pexidartinib | hsa04064 | NF-kappa B signaling pathway | 1.48E-07 | 22 | P10415, Q13489, O00463, P14778, P01584, P29965, P19174, Q04759, Q9UDY8, Q13077, Q16548, P07948, P06239, Q8WV28, Q13315, P63279, P24522, Q8NHW4, P09341, P19875, Q06643, Q9NQC7 | BCL2, BIRC3, TRAF5, IL1R1, IL1B, CD40LG, PLCG1, PRKCQ, MALT1, TRAF1, BCL2A1, LYN, LCK, BLNK, ATM, UBE2I, GADD45A, CCL4L2, CXCL1, CXCL2, LTB, CYLD | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P17252 | PRKCA | Protein kinase C alpha type | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.844 | P17252 | PRKCA | Protein kinase C alpha type | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | 0.849 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.837 | P06239 | LCK | Tyrosine-protein kinase Lck | O00463 | TRAF5 | TNF receptor-associated factor 5 | 0.718 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.76 | P06239 | LCK | Tyrosine-protein kinase Lck | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.782 | Q13547 | HDAC1 | Histone deacetylase 1 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.854 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | P01584 | IL1B | Interleukin-1 beta | 0.735 | P17252 | PRKCA | Protein kinase C alpha type | P29965 | CD40LG | CD40 ligand | 0.788 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | Q13547 | HDAC1 | Histone deacetylase 1 | Q04759 | PRKCQ | Protein kinase C theta type | 0.723 | P17252 | PRKCA | Protein kinase C alpha type | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | 0.769 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.73 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.875 | P06239 | LCK | Tyrosine-protein kinase Lck | P07948 | LYN | Tyrosine-protein kinase Lyn | -0.701 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P17252 | PRKCA | Protein kinase C alpha type | Q8WV28 | BLNK | B-cell linker protein | 0.838 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q8WV28 | BLNK | B-cell linker protein | -0.816 | P17252 | PRKCA | Protein kinase C alpha type | Q13315 | ATM | Serine-protein kinase ATM | 0.739 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | P63279 | UBE2I | SUMO-conjugating enzyme UBC9 | 0.739 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.796 | P06239 | LCK | Tyrosine-protein kinase Lck | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.724 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.756 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.756 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P09341 | CXCL1 | Growth-regulated alpha protein | 0.7 | P06239 | LCK | Tyrosine-protein kinase Lck | P09341 | CXCL1 | Growth-regulated alpha protein | -0.805 | Q13547 | HDAC1 | Histone deacetylase 1 | P09341 | CXCL1 | Growth-regulated alpha protein | -0.736 | Q13547 | HDAC1 | Histone deacetylase 1 | P19875 | CXCL2 | C-X-C motif chemokine 2 | -0.862 | P06239 | LCK | Tyrosine-protein kinase Lck | Q06643 | LTB | Lymphotoxin-beta | 0.846 | Q13547 | HDAC1 | Histone deacetylase 1 | Q06643 | LTB | Lymphotoxin-beta | 0.74 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | Q9NQC7 | CYLD | Ubiquitin carboxyl-terminal hydrolase CYLD | 0.753 |
| Pexidartinib | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P04049 | RAF1 | More | | Pexidartinib | hsa04070 | Phosphatidylinositol signaling system | 8.69E-05 | 9 | P0DP23, Q14643, O14986, P23743, Q86XP1, Q16760, P48426, Q96DU7, P17252 | CALM1, ITPR1, PIP5K1B, DGKA, DGKH, DGKD, PIP4K2A, ITPKC, PRKCA | More | | Pexidartinib | hsa04071 | Sphingolipid signaling pathway | 6.63E-04 | 8 | P04049, P17252, P21453, Q9H228, P01375, Q13362, Q9BX95, P10415 | RAF1, PRKCA, S1PR1, EDG8, TNF, PPP2R5C, SGPP1, BCL2 | More | | Pexidartinib | hsa04072 | Phospholipase D signaling pathway | 2.43E-04 | 12 | P04049, P31751, P42338, P43657, P25024, P25025, P19174, O14986, Q15438, Q08828, P51828, Q16760 | RAF1, AKT2, PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1, PIP5K1B, PSCD1, ADCY1, ADCY7, DGKD | More | | Pexidartinib | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | | Pexidartinib | hsa04110 | Cell cycle | 8.83E-05 | 8 | Q9UBD5, P06493, O60566, Q14683, P30304, P33981, P42773, P01106 | ORC3, CDK1, BUB1B, SMC1A, CDC25A, TTK, CDKN2C, MYC | More | | Pexidartinib | hsa04114 | Oocyte meiosis | 1.06E-05 | 10 | Q9Y6D9, P51812, Q02750, P0DP23, P16298, Q17RY0, Q08828, P51828, Q13362, Q14738 | MAD1L1, RPS6KA3, MAP2K1, CALM1, PPP3CB, CPEB4, ADCY1, ADCY7, PPP2R5C, PPP2R5D | More | | Pexidartinib | hsa04120 | Ubiquitin mediated proteolysis | 1.08E-03 | 6 | Q9UBT2, Q14145, Q13042, P62837, Q15751, Q14669 | SAE2, KEAP1, CDC16, UBE2D2, HERC1, TRIP12 | More | | Pexidartinib | hsa04136 | Autophagy - other | 5.92E-03 | 2 | O94817, Q9H1Y0 | ATG12, ATG5 | More | | Pexidartinib | hsa04140 | Autophagy - animal | 4.41E-03 | 6 | P31751, P04049, Q7L523, O75460, Q96GC9, Q8TEV9 | AKT2, RAF1, RRAGA, ERN1, TMEM49, SMCR8 | More | | Pexidartinib | hsa04145 | Phagosome | 1.59E-03 | 7 | Q15080, P14598, Q13509, P68371, Q13488, O60603, P13765 | NCF4, NCF1, TUBB3, TUBB2C, TCIRG1, TLR2, HLA-DOB | More | | Pexidartinib | hsa04150 | mTOR signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | | Pexidartinib | hsa04151 | PI3K-Akt signaling pathway | 7.38E-03 | 11 | P25116, P49767, Q13362, P62873, P16144, P02452, P24821, O60603, P01568, P10415, P17252 | F2R, VEGFC, PPP2R5C, GNB1, ITGB4, COL1A1, TNC, TLR2, IFNA21, BCL2, PRKCA | More | | Pexidartinib | hsa04210 | Apoptosis | 2.16E-02 | 1 | P04049 | RAF1 | More | | Pexidartinib | hsa04211 | Longevity regulating pathway | 1.88E-02 | 4 | P31751, Q08828, P51828, P18848 | AKT2, ADCY1, ADCY7, ATF4 | More | | Pexidartinib | hsa04213 | Longevity regulating pathway - multiple species | 4.29E-03 | 7 | P31751, P42338, Q9Y4H2, Q08828, P51828, P11142, Q13547 | AKT2, PIK3CB, IRS2, ADCY1, ADCY7, HSPA8, HDAC1 | More | | Pexidartinib | hsa04217 | Necroptosis | 1.08E-06 | 17 | P01375, P01568, P48023, Q13489, Q9NQC7, Q13546, P42224, Q14765, P07900, P15104, P01584, Q6FI13, Q99878, P10415, Q9H444, O43633, Q08752 | TNF, IFNA21, FASLG, BIRC3, CYLD, RIPK1, STAT1, STAT4, HSP90AA1, GLUL, IL1B, H2AC18; H2AC19, H2AC14, BCL2, CHMP4B, CHMP2A, PPID | More | | Pexidartinib | hsa04218 | Cellular senescence | 1.43E-04 | 3 | P31751, P04049, P0DP23 | AKT2, RAF1, CALM1 | More | | Pexidartinib | hsa04261 | Adrenergic signaling in cardiomyocytes | 8.93E-07 | 12 | P09493, P07550, Q08828, P51828, P22694, P31751, P18848, Q13362, Q14738, P0DP23, P17252, P10415 | TPM1, ADRB2, ADCY1, ADCY7, PRKACB, AKT2, ATF4, PPP2R5C, PPP2R5D, CALM1, PRKCA, BCL2 | More | | Pexidartinib | hsa04270 | Vascular smooth muscle contraction | 2.32E-02 | 1 | P04049 | RAF1 | More | | Pexidartinib | hsa04310 | Wnt signaling pathway | 1.79E-02 | 2 | P17612, P67870 | PRKACA, CSNK2B | More | | Pexidartinib | hsa04330 | Notch signaling pathway | 2.77E-02 | 2 | Q92542, P49768 | NCSTN, PSEN1 | More | | Pexidartinib | hsa04340 | Hedgehog signaling pathway | 1.71E-03 | 2 | P17612, Q9Y496 | PRKACA, KIF3A | More | | Pexidartinib | hsa04360 | Axon guidance | 2.49E-02 | 1 | P04049 | RAF1 | More | | Pexidartinib | hsa04370 | VEGF signaling pathway | 6.68E-07 | 5 | P16298, P31751, Q05397, Q02750, P04049 | PPP3CB, AKT2, PTK2, MAP2K1, RAF1 | More | | Pexidartinib | hsa04371 | Apelin signaling pathway | 6.08E-04 | 5 | P31751, P04049, Q08828, P51828, P0DP23 | AKT2, RAF1, ADCY1, ADCY7, CALM1 | More | | Pexidartinib | hsa04380 | Osteoclast differentiation | 2.07E-05 | 10 | Q9NQC7, Q9UQC2, Q16539, P23458, P31751, P01584, P14778, O75015, P01375, Q8N149 | CYLD, GAB2, MAPK14, JAK1, AKT2, IL1B, IL1R1, FCGR3B, TNF, LILRA2 | More | | Pexidartinib | hsa04390 | Hippo signaling pathway | 2.41E-02 | 2 | P04628, O43623 | WNT1, SNAI2 | More | | Pexidartinib | hsa04392 | Hippo signaling pathway - multiple species | 7.65E-04 | 2 | Q13153, Q6V0I7 | PAK1, FAT4 | More | | Pexidartinib | hsa04510 | Focal adhesion | 3.48E-02 | 1 | P04049 | RAF1 | More | | Pexidartinib | hsa04512 | ECM-receptor interaction | 3.33E-04 | 4 | P02452, P24821, P26012, P16070 | COL1A1, TNC, ITGB8, CD44 | More | | Pexidartinib | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Pexidartinib | hsa04540 | Gap junction | 2.79E-03 | 5 | P17252, Q13509, P68371, P04049, Q14643 | PRKCA, TUBB3, TUBB2C, RAF1, ITPR1 | More | | Pexidartinib | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 9.61E-03 | 4 | Q13873, P04049, Q02750, Q86SE9 | BMPR2, RAF1, MAP2K1, PCGF5 | More | | Pexidartinib | hsa04610 | Complement and coagulation cascades | 1.19E-06 | 2 | P00734, P0C0L4 | F2, C4A | More | | Pexidartinib | hsa04611 | Platelet activation | 2.12E-02 | 2 | Q9Y490, P17612 | TLN1, PRKACA | More | | Pexidartinib | hsa04612 | Antigen processing and presentation | 2.51E-06 | 9 | P13765, P01730, Q14953, P26715, P26717, Q07444, Q13241, P01732, P01375 | HLA-DOB, CD4, KIR2DS5, KLRC1, KLRC2, KLRC3, KLRD1, CD8A, TNF | More | | Pexidartinib | hsa04613 | Neutrophil extracellular trap formation | 3.41E-05 | 15 | P17252, P04049, O60603, P08246, P04908, Q6FI13, Q93077, P62807, O60814, P68431, P14598, Q15080, P21462, O43315, Q16539 | PRKCA, RAF1, TLR2, ELA2, H2AC4; H2AC8, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, FPR1, AQP9, MAPK14 | More | | Pexidartinib | hsa04620 | Toll-like receptor signaling pathway | 2.48E-05 | 5 | Q13546, P01568, P01584, P31751, Q8NHW4 | RIPK1, IFNA21, IL1B, AKT2, CCL4L2 | More | | Pexidartinib | hsa04621 | NOD-like receptor signaling pathway | 2.92E-02 | 3 | P01584, P07900, P43490 | IL1B, HSP90AA1, PBEF1 | More | | Pexidartinib | hsa04622 | RIG-I-like receptor signaling pathway | 1.88E-04 | 3 | P01568, Q9NQC7, Q13546 | IFNA21, CYLD, RIPK1 | More | | Pexidartinib | hsa04623 | Cytosolic DNA-sensing pathway | 2.07E-07 | 5 | P01584, P01568, Q13546, Q9Y535, Q8NHW4 | IL1B, IFNA21, RIPK1, POLR3H, CCL4L2 | More | | Pexidartinib | hsa04625 | C-type lectin receptor signaling pathway | 1.92E-07 | 10 | Q9ULY5, P04049, Q13153, P01584, Q9NQC7, P20749, P01375, P31751, P0DP23, Q16539 | CLEC4E, RAF1, PAK1, IL1B, CYLD, BCL3, TNF, AKT2, CALM1, MAPK14 | More | | Pexidartinib | hsa04630 | JAK-STAT signaling pathway | 8.73E-03 | 4 | P31751, P23458, Q13651, P04049 | AKT2, JAK1, IL10RA, RAF1 | More | | Pexidartinib | hsa04640 | Hematopoietic cell lineage | 2.06E-06 | 12 | P13612, P14778, P27930, P11215, P25063, P07766, P09693, P01732, P01730, P06127, P09564, P13765 | ITGA4, IL1R1, IL1R2, ITGAM, CD24, CD3E, CD3G, CD8A, CD4, CD5, CD7, HLA-DOB | More | | Pexidartinib | hsa04650 | Natural killer cell mediated cytotoxicity | 2.82E-14 | 18 | P16298, P50591, P19174, P01375, P06239, O60880, P20963, P42338, Q02750, P04049, Q13153, Q13241, P26718, O14931, P26717, Q07444, Q14953, P26715 | PPP3CB, TNFSF10, PLCG1, TNF, LCK, SH2D1A, CD247, PIK3CB, MAP2K1, RAF1, PAK1, KLRD1, KLRK1, NCR3, KLRC2, KLRC3, KIR2DS5, KLRC1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q05397 | PTK2 | Focal adhesion kinase 1 | P16298 | PPP3CB | Serine/threonine-protein phosphatase 2B catalytic subunit beta isoform | 0.919 | Q05397 | PTK2 | Focal adhesion kinase 1 | P50591 | TNFSF10 | Tumor necrosis factor ligand superfamily member 10 | 0.849 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.771 | P06239 | LCK | Tyrosine-protein kinase Lck | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.906 | Q13547 | HDAC1 | Histone deacetylase 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.786 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q13547 | HDAC1 | Histone deacetylase 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.87 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.797 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.727 | Q13547 | HDAC1 | Histone deacetylase 1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.774 | Q05397 | PTK2 | Focal adhesion kinase 1 | Q02750 | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | 0.898 | P04049 | RAF1 | RAF proto-oncogene serine/threonine-protein kinase | P04049 | RAF1 | RAF proto-oncogene serine/threonine-protein kinase | 1 | Q13153 | PAK1 | Serine/threonine-protein kinase PAK 1 | Q13153 | PAK1 | Serine/threonine-protein kinase PAK 1 | 1 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.758 | Q13547 | HDAC1 | Histone deacetylase 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.807 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.78 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | P06239 | LCK | Tyrosine-protein kinase Lck | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.886 | Q13547 | HDAC1 | Histone deacetylase 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.772 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.767 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.701 | P06239 | LCK | Tyrosine-protein kinase Lck | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.732 | Q13547 | HDAC1 | Histone deacetylase 1 | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.735 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.818 | P06239 | LCK | Tyrosine-protein kinase Lck | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.756 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.726 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | Q07444 | KLRC3 | NKG2-E type II integral membrane protein | 0.829 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | P06239 | LCK | Tyrosine-protein kinase Lck | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.756 | P00352 | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.726 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 |
| Pexidartinib | hsa04657 | IL-17 signaling pathway | 1.01E-05 | 10 | P07900, O00463, Q16539, P49841, P09341, P19875, P14780, P80188, P01375, P01584 | HSP90AA1, TRAF5, MAPK14, GSK3B, CXCL1, CXCL2, MMP9, LCN2, TNF, IL1B | More | | Pexidartinib | hsa04658 | Th1 and Th2 cell differentiation | 9.50E-14 | 12 | Q04759, P07766, P20963, P09693, P19174, P01730, P06239, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, PLCG1, CD4, LCK, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | | Pexidartinib | hsa04659 | Th17 cell differentiation | 3.03E-10 | 12 | Q04759, P19174, P01730, P06239, P14784, P13765, P14778, Q9UL17, P23771, P07766, P09693, P20963 | PRKCQ, PLCG1, CD4, LCK, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, CD3E, CD3G, CD247 | More | | Pexidartinib | hsa04660 | T cell receptor signaling pathway | 1.39E-10 | 14 | Q04759, P42338, O95267, Q08881, P19174, Q13153, P07766, P20963, P09693, P01730, P01732, Q13191, P06239, P04049 | PRKCQ, PIK3CB, RASGRP1, ITK, PLCG1, PAK1, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK, RAF1 | More | | Pexidartinib | hsa04662 | B cell receptor signaling pathway | 1.12E-03 | 2 | P31751, P04049 | AKT2, RAF1 | More | | Pexidartinib | hsa04664 | Fc epsilon RI signaling pathway | 1.50E-03 | 5 | P01375, P31751, Q16539, Q9UQC2, P04049 | TNF, AKT2, MAPK14, GAB2, RAF1 | More | | Pexidartinib | hsa04666 | Fc gamma R-mediated phagocytosis | 2.32E-02 | 1 | P04049 | RAF1 | More | | Pexidartinib | hsa04668 | TNF signaling pathway | 2.12E-03 | 7 | P01375, O00463, Q16539, P18848, P19875, P20749, P14780 | TNF, TRAF5, MAPK14, ATF4, CXCL2, BCL3, MMP9 | More | | Pexidartinib | hsa04672 | Intestinal immune network for IgA production | 3.76E-03 | 3 | P29965, P10747, P13765 | CD40LG, CD28, HLA-DOB | More | | Pexidartinib | hsa04710 | Circadian rhythm | 4.40E-02 | 1 | O15516 | CLOCK | More | | Pexidartinib | hsa04713 | Circadian entrainment | 2.85E-03 | 6 | P0DP23, P17252, P62873, Q14643, Q08828, P51828 | CALM1, PRKCA, GNB1, ITPR1, ADCY1, ADCY7 | More | | Pexidartinib | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | Pexidartinib | hsa04720 | Long-term potentiation | 1.71E-05 | 9 | P17252, P16298, P0DP23, P51812, P18848, Q08828, Q02750, P04049, Q14643 | PRKCA, PPP3CB, CALM1, RPS6KA3, ATF4, ADCY1, MAP2K1, RAF1, ITPR1 | More | | Pexidartinib | hsa04722 | Neurotrophin signaling pathway | 2.01E-04 | 6 | P31751, P04049, P49841, O43524, P48023, P0DP23 | AKT2, RAF1, GSK3B, FOXO3, FASLG, CALM1 | More | | Pexidartinib | hsa04723 | Retrograde endocannabinoid signaling | 1.88E-02 | 4 | Q14643, P17252, P62873, Q16718 | ITPR1, PRKCA, GNB1, NDUFA5 | More | | Pexidartinib | hsa04725 | Cholinergic synapse | 7.24E-04 | 8 | Q08828, P51828, Q14643, P17252, P62873, P18848, P31751, P10415 | ADCY1, ADCY7, ITPR1, PRKCA, GNB1, ATF4, AKT2, BCL2 | More | | Pexidartinib | hsa04726 | Serotonergic synapse | 1.33E-02 | 1 | P04049 | RAF1 | More | | Pexidartinib | hsa04728 | Dopaminergic synapse | 7.82E-05 | 8 | Q14643, P17252, P62873, P31751, P18848, Q13362, Q14738, P0DP23 | ITPR1, PRKCA, GNB1, AKT2, ATF4, PPP2R5C, PPP2R5D, CALM1 | More | | Pexidartinib | hsa04730 | Long-term depression | 1.16E-02 | 1 | P04049 | RAF1 | More | | Pexidartinib | hsa04740 | Olfactory transduction | 2.41E-02 | 1 | P0DP23 | CALM1 | More | | Pexidartinib | hsa04742 | Taste transduction | 3.91E-02 | 1 | P17612 | PRKACA | More | | Pexidartinib | hsa04744 | Phototransduction | 1.74E-03 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Pexidartinib | hsa04750 | Inflammatory mediator regulation of TRP channels | 2.03E-04 | 9 | P14778, P01584, Q08828, P51828, P19174, P42338, P24723, Q04759, P0DP23 | IL1R1, IL1B, ADCY1, ADCY7, PLCG1, PIK3CB, PRKCH, PRKCQ, CALM1 | More | | Pexidartinib | hsa04810 | Regulation of actin cytoskeleton | 3.81E-02 | 1 | P04049 | RAF1 | More | | Pexidartinib | hsa04910 | Insulin signaling pathway | 2.40E-05 | 3 | P0DP23, P04049, P31751 | CALM1, RAF1, AKT2 | More | | Pexidartinib | hsa04911 | Insulin secretion | 2.40E-02 | 3 | Q08828, P51828, P18848 | ADCY1, ADCY7, ATF4 | More | | Pexidartinib | hsa04912 | GnRH signaling pathway | 6.90E-04 | 7 | P17252, Q08828, P51828, P18848, Q14643, P0DP23, P04049 | PRKCA, ADCY1, ADCY7, ATF4, ITPR1, CALM1, RAF1 | More | | Pexidartinib | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | Pexidartinib | hsa04914 | Progesterone-mediated oocyte maturation | 1.19E-04 | 5 | Q17RY0, Q9Y6D9, P51812, Q02750, P04049 | CPEB4, MAD1L1, RPS6KA3, MAP2K1, RAF1 | More | | Pexidartinib | hsa04915 | Estrogen signaling pathway | 3.57E-04 | 6 | P04049, P18848, Q08828, P51828, P31751, P0DP23 | RAF1, ATF4, ADCY1, ADCY7, AKT2, CALM1 | More | | Pexidartinib | hsa04916 | Melanogenesis | 7.31E-04 | 4 | P0DP23, Q08828, P51828, P04049 | CALM1, ADCY1, ADCY7, RAF1 | More | | Pexidartinib | hsa04917 | Prolactin signaling pathway | 3.49E-04 | 2 | P31751, P04049 | AKT2, RAF1 | More | | Pexidartinib | hsa04919 | Thyroid hormone signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | | Pexidartinib | hsa04920 | Adipocytokine signaling pathway | 4.19E-02 | 1 | P31751 | AKT2 | More | | Pexidartinib | hsa04921 | Oxytocin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | | Pexidartinib | hsa04922 | Glucagon signaling pathway | 3.10E-04 | 7 | P14618, P06737, Q12778, P31751, Q13370, P0DP23, Q14643 | PKM2, PYGL, FOXO1, AKT2, PDE3B, CALM1, ITPR1 | More | | Pexidartinib | hsa04923 | Regulation of lipolysis in adipocytes | 5.39E-05 | 6 | Q08828, P51828, P07550, P42338, Q9Y4H2, P31751 | ADCY1, ADCY7, ADRB2, PIK3CB, IRS2, AKT2 | More | | Pexidartinib | hsa04924 | Renin secretion | 1.57E-04 | 5 | P22694, P07550, Q14643, Q13370, P0DP23 | PRKACB, ADRB2, ITPR1, PDE3B, CALM1 | More | | Pexidartinib | hsa04925 | Aldosterone synthesis and secretion | 9.86E-03 | 4 | P18848, Q08828, P51828, P0DP23 | ATF4, ADCY1, ADCY7, CALM1 | More | | Pexidartinib | hsa04926 | Relaxin signaling pathway | 4.96E-04 | 8 | P31751, P18848, P22694, P14780, Q08828, P51828, P04049, P30679 | AKT2, ATF4, PRKACB, MMP9, ADCY1, ADCY7, RAF1, GNA15 | More | | Pexidartinib | hsa04927 | Cortisol synthesis and secretion | 7.43E-04 | 4 | P18848, Q08828, P51828, P22694 | ATF4, ADCY1, ADCY7, PRKACB | More | | Pexidartinib | hsa04928 | Parathyroid hormone synthesis, secretion and action | 1.99E-02 | 1 | P04049 | RAF1 | More | | Pexidartinib | hsa04929 | GnRH secretion | 1.87E-04 | 2 | P31751, P04049 | AKT2, RAF1 | More | | Pexidartinib | hsa04932 | Non-alcoholic fatty liver disease | 6.56E-06 | 12 | P31751, P01375, P49841, P18848, P48023, O75460, P01584, P12074, O15239, Q16718, O95298, O14521 | AKT2, TNF, GSK3B, ATF4, FASLG, ERN1, IL1B, COX6A1, NDUFA1, NDUFA5, NDUFC2, SDHD | More | | Pexidartinib | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.27E-02 | 5 | P42224, P10415, Q12778, P49767, P17252 | STAT1, BCL2, FOXO1, VEGFC, PRKCA | More | | Pexidartinib | hsa04934 | Cushing syndrome | 4.54E-02 | 3 | P18848, Q08828, P51828 | ATF4, ADCY1, ADCY7 | More | | Pexidartinib | hsa04935 | Growth hormone synthesis, secretion and action | 5.00E-03 | 5 | Q08828, P51828, P04049, P18848, P31751 | ADCY1, ADCY7, RAF1, ATF4, AKT2 | More | | Pexidartinib | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Pexidartinib | hsa04960 | Aldosterone-regulated sodium reabsorption | 4.40E-02 | 1 | O00141 | SGK | More | | Pexidartinib | hsa04964 | Proximal tubule bicarbonate reclamation | 4.48E-02 | 1 | P00918 | CA2 | More | | Pexidartinib | hsa04966 | Collecting duct acid secretion | 1.95E-03 | 3 | Q13488, P00918, Q9Y666 | TCIRG1, CA2, SLC12A7 | More | | Pexidartinib | hsa04970 | Salivary secretion | 1.35E-04 | 6 | P07550, Q08828, P51828, P22694, P0DP23, P49913 | ADRB2, ADCY1, ADCY7, PRKACB, CALM1, CAMP | More | | Pexidartinib | hsa04971 | Gastric acid secretion | 4.91E-04 | 4 | Q08828, P51828, P15311, P0DP23 | ADCY1, ADCY7, VIL2, CALM1 | More | | Pexidartinib | hsa04973 | Carbohydrate digestion and absorption | 4.61E-03 | 3 | O43451, P42338, P31751 | MGAM, PIK3CB, AKT2 | More | | Pexidartinib | hsa04974 | Protein digestion and absorption | 2.78E-02 | 1 | P02452 | COL1A1 | More | | Pexidartinib | hsa04976 | Bile secretion | 9.77E-04 | 5 | O43315, Q08828, P51828, P08183, Q14032 | AQP9, ADCY1, ADCY7, ABCB1, BAAT | More | | Pexidartinib | hsa05010 | Alzheimer disease | 1.12E-04 | 15 | Q16718, O95298, O14521, Q14643, Q00535, O75460, P0DP23, P01584, P18848, Q13509, P68371, P31751, P05141, Q08752, P28070 | NDUFA5, NDUFC2, SDHD, ITPR1, CDK5, ERN1, CALM1, IL1B, ATF4, TUBB3, TUBB2C, AKT2, SLC25A5, PPID, PSMB4 | More | | Pexidartinib | hsa05012 | Parkinson disease | 2.25E-02 | 6 | Q16718, O14521, Q14643, P0DP23, Q13509, P68371 | NDUFA5, SDHD, ITPR1, CALM1, TUBB3, TUBB2C | More | | Pexidartinib | hsa05016 | Huntington disease | 2.24E-02 | 7 | O95298, P24928, P30876, P62487, P05141, O75460, P28070 | NDUFC2, POLR2A, POLR2B, POLR2G, SLC25A5, ERN1, PSMB4 | More | | Pexidartinib | hsa05017 | Spinocerebellar ataxia | 3.94E-02 | 4 | O75460, P31751, P28070, P05141 | ERN1, AKT2, PSMB4, SLC25A5 | More | | Pexidartinib | hsa05020 | Prion disease | 1.31E-03 | 9 | Q16718, O14521, Q14643, Q13509, P68371, P49841, P14598, Q15080, Q16539 | NDUFA5, SDHD, ITPR1, TUBB3, TUBB2C, GSK3B, NCF1, NCF4, MAPK14 | More | | Pexidartinib | hsa05022 | Pathways of neurodegeneration - multiple diseases | 3.19E-06 | 22 | Q14643, Q13509, P68371, P49841, P10415, Q16718, O95298, O14521, Q06055, Q8TEV9, O75460, P18848, Q13561, P05141, P17252, Q16539, Q00535, P01584, Q08752, O15020, P0DP23, P28070 | ITPR1, TUBB3, TUBB2C, GSK3B, BCL2, NDUFA5, NDUFC2, SDHD, ATP5G2, SMCR8, ERN1, ATF4, DCTN2, SLC25A5, PRKCA, MAPK14, CDK5, IL1B, PPID, SPTBN2, CALM1, PSMB4 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P17252 | PRKCA | Protein kinase C alpha type | Q14643 | ITPR1 | Inositol 1,4,5-trisphosphate receptor type 1 | 0.786 | P17252 | PRKCA | Protein kinase C alpha type | Q13509 | TUBB3 | Tubulin beta-3 chain | -0.756 | P17252 | PRKCA | Protein kinase C alpha type | P68371 | TUBB2C | Tubulin beta-4B chain | -0.842 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | P49841 | GSK3B | Glycogen synthase kinase-3 beta | -0.714 | P17252 | PRKCA | Protein kinase C alpha type | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.844 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | Q16718 | NDUFA5 | NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 | 0.757 | P17252 | PRKCA | Protein kinase C alpha type | Q16718 | NDUFA5 | NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 | 0.811 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | O95298 | NDUFC2 | NADH dehydrogenase [ubiquinone] 1 subunit C2 | 0.778 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | O14521 | SDHD | Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial | 0.732 | P17252 | PRKCA | Protein kinase C alpha type | O14521 | SDHD | Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial | 0.822 | P30530 | AXL | Tyrosine-protein kinase receptor UFO | Q06055 | ATP5G2 | ATP synthase F(0) complex subunit C2, mitochondrial | -0.735 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | Q8TEV9 | SMCR8 | Guanine nucleotide exchange protein SMCR8 | 0.807 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | O75460 | ERN1 | Serine/threonine-protein kinase/endoribonuclease IRE1 | 0.734 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | P18848 | ATF4 | Cyclic AMP-dependent transcription factor ATF-4 | 0.748 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | Q13561 | DCTN2 | Dynactin subunit 2 | -0.771 | P17252 | PRKCA | Protein kinase C alpha type | Q13561 | DCTN2 | Dynactin subunit 2 | -0.844 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | P05141 | SLC25A5 | ADP/ATP translocase 2 | 0.779 | P17252 | PRKCA | Protein kinase C alpha type | P17252 | PRKCA | Protein kinase C alpha type | 1 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | -0.744 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | 1 | P31751 | AKT2 | RAC-beta serine/threonine-protein kinase | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | 0.726 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | P01584 | IL1B | Interleukin-1 beta | 0.735 | P31645 | SLC6A4 | Sodium-dependent serotonin transporter | Q08752 | PPID | Peptidyl-prolyl cis-trans isomerase D | 0.859 | P17252 | PRKCA | Protein kinase C alpha type | Q08752 | PPID | Peptidyl-prolyl cis-trans isomerase D | 0.725 | P30530 | AXL | Tyrosine-protein kinase receptor UFO | O15020 | SPTBN2 | Spectrin beta chain, non-erythrocytic 2 | 0.738 | P17252 | PRKCA | Protein kinase C alpha type | P0DP23 | CALM1 | Calmodulin-1 | -0.776 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | P0DP23 | CALM1 | Calmodulin-1 | 0.857 | P31751 | AKT2 | RAC-beta serine/threonine-protein kinase | P0DP23 | CALM1 | Calmodulin-1 | 0.761 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | P28070 | PSMB4 | Proteasome subunit beta type-4 | 0.736 |
| Pexidartinib | hsa05030 | Cocaine addiction | 4.19E-02 | 1 | Q00535 | CDK5 | More | | Pexidartinib | hsa05031 | Amphetamine addiction | 6.98E-03 | 4 | P0DP23, P22694, P18848, Q13547 | CALM1, PRKACB, ATF4, HDAC1 | More | | Pexidartinib | hsa05034 | Alcoholism | 2.78E-04 | 5 | P04049, Q93077, P62807, O60814, P68431 | RAF1, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Pexidartinib | hsa05100 | Bacterial invasion of epithelial cells | 2.85E-02 | 3 | Q14141, Q05397, Q96JJ3 | SEPT6, PTK2, ELMO2 | More | | Pexidartinib | hsa05110 | Vibrio cholerae infection | 2.11E-03 | 2 | Q99437, P17612 | ATP6V0B, PRKACA | More | | Pexidartinib | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.27E-05 | 7 | Q16539, Q13153, P09341, P19875, P19174, P25024, P25025 | MAPK14, PAK1, CXCL1, CXCL2, PLCG1, CXCR1, CXCR2 | More | | Pexidartinib | hsa05131 | Shigellosis | 2.27E-02 | 8 | P68431, Q9UDY8, Q14247, Q14643, Q12778, Q13315, P10415, Q08752 | H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, MALT1, CTTN, ITPR1, FOXO1, ATM, BCL2, PPID | More | | Pexidartinib | hsa05132 | Salmonella infection | 7.93E-03 | 9 | P04049, Q9UJU2, Q13489, P10415, O60603, Q9BQS8, Q13561, Q13509, P68371 | RAF1, LEF1, BIRC3, BCL2, TLR2, FYCO1, DCTN2, TUBB3, TUBB2C | More | | Pexidartinib | hsa05133 | Pertussis | 2.35E-03 | 2 | P0DP23, P0C0L4 | CALM1, C4A | More | | Pexidartinib | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | | Pexidartinib | hsa05135 | Yersinia infection | 3.29E-02 | 4 | Q05397, P51812, Q02750, Q96JJ3 | PTK2, RPS6KA3, MAP2K1, ELMO2 | More | | Pexidartinib | hsa05140 | Leishmaniasis | 2.04E-04 | 9 | O75015, P14598, P42224, P13765, O60603, P29350, P49006, Q16539, Q15080 | FCGR3B, NCF1, STAT1, HLA-DOB, TLR2, PTPN6, MARCKSL1, MAPK14, NCF4 | More | | Pexidartinib | hsa05143 | African trypanosomiasis | 2.12E-04 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | | Pexidartinib | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | | Pexidartinib | hsa05145 | Toxoplasmosis | 1.11E-02 | 6 | P10415, Q13489, P42224, P13765, O60603, P29965 | BCL2, BIRC3, STAT1, HLA-DOB, TLR2, CD40LG | More | | Pexidartinib | hsa05146 | Amoebiasis | 1.52E-08 | 13 | P09341, P19875, P14778, P27930, P01375, O60603, P42338, P11215, P05089, P30679, P22694, P12814, P08311 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, PIK3CB, ITGAM, ARG1, GNA15, PRKACB, ACTN1, CTSG | More | | Pexidartinib | hsa05150 | Staphylococcus aureus infection | 1.16E-03 | 6 | P0C0L4, P13646, Q14532, P59665, P59666, P49913 | C4A, KRT13, KRT32, DEFA1; DEFA1B, DEFA3, CAMP | More | | Pexidartinib | hsa05152 | Tuberculosis | 1.60E-04 | 10 | P04049, Q13488, P0DP23, P42224, O60603, P31751, P10415, P13765, P01568, Q9UDY8 | RAF1, TCIRG1, CALM1, STAT1, TLR2, AKT2, BCL2, HLA-DOB, IFNA21, MALT1 | More | | Pexidartinib | hsa05160 | Hepatitis C | 1.31E-04 | 7 | Q13546, P01568, P60033, P04049, P49841, P01375, P48023 | RIPK1, IFNA21, CD81, RAF1, GSK3B, TNF, FASLG | More | | Pexidartinib | hsa05161 | Hepatitis B | 1.99E-02 | 1 | P04049 | RAF1 | More | | Pexidartinib | hsa05163 | Human cytomegalovirus infection | 1.49E-06 | 18 | P31751, P04049, P01375, Q14643, P0DP23, Q8NHW4, Q08828, P51828, P23458, P49841, P14778, P01584, Q13651, P25025, Q16539, P18848, P04637, O00463 | AKT2, RAF1, TNF, ITPR1, CALM1, CCL4L2, ADCY1, ADCY7, JAK1, GSK3B, IL1R1, IL1B, IL10RA, CXCR2, MAPK14, ATF4, TP53, TRAF5 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | P31751 | AKT2 | RAC-beta serine/threonine-protein kinase | 0.726 | P31751 | AKT2 | RAC-beta serine/threonine-protein kinase | P31751 | AKT2 | RAC-beta serine/threonine-protein kinase | 1 | P04049 | RAF1 | RAF proto-oncogene serine/threonine-protein kinase | P04049 | RAF1 | RAF proto-oncogene serine/threonine-protein kinase | 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | P01375 | TNF | Tumor necrosis factor | 0.732 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q14643 | ITPR1 | Inositol 1,4,5-trisphosphate receptor type 1 | -0.728 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | P0DP23 | CALM1 | Calmodulin-1 | 0.857 | P31751 | AKT2 | RAC-beta serine/threonine-protein kinase | P0DP23 | CALM1 | Calmodulin-1 | 0.761 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.756 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.756 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | Q08828 | ADCY1 | Adenylate cyclase type 1 | 0.796 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | P51828 | ADCY7 | Adenylate cyclase type 7 | 0.726 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | 0.842 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.78 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.76 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.778 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | P01584 | IL1B | Interleukin-1 beta | 0.735 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | Q13651 | IL10RA | Interleukin-10 receptor subunit alpha | 0.786 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.889 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.861 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.78 | Q00535 | CDK5 | Cyclin-dependent-like kinase 5 | P18848 | ATF4 | Cyclic AMP-dependent transcription factor ATF-4 | 0.748 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P04637 | TP53 | Cellular tumor antigen p53 | -0.823 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.837 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.734 |
| Pexidartinib | hsa05164 | Influenza A | 1.49E-02 | 6 | P31751, P01584, P23458, P05141, P04049, Q9UBU9 | AKT2, IL1B, JAK1, SLC25A5, RAF1, NXF1 | More | | Pexidartinib | hsa05165 | Human papillomavirus infection | 9.67E-04 | 11 | P16144, P02452, P24821, Q05086, P01568, P42224, Q13488, Q13362, Q12778, P04628, Q13315 | ITGB4, COL1A1, TNC, UBE3A, IFNA21, STAT1, TCIRG1, PPP2R5C, FOXO1, WNT1, ATM | More | | Pexidartinib | hsa05166 | Human T-cell leukemia virus 1 infection | 3.90E-02 | 7 | P23458, P05141, P62826, Q08828, P51828, P18848, P31751 | JAK1, SLC25A5, RAN, ADCY1, ADCY7, ATF4, AKT2 | More | | Pexidartinib | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.26E-03 | 8 | P01568, P31751, P42224, P62873, Q14643, P04049, P0DP23, Q9UJU2 | IFNA21, AKT2, STAT1, GNB1, ITPR1, RAF1, CALM1, LEF1 | More | | Pexidartinib | hsa05168 | Herpes simplex virus 1 infection | 4.79E-02 | 8 | P25963, Q07955, Q01130, Q9Y2A4, P51522, P17038, P52738, O75820 | NFKBIA, SFRS1, SFRS2, ZNF443, ZNF83, ZNF43, ZNF140, ZNF189 | More | | Pexidartinib | hsa05169 | Epstein-Barr virus infection | 4.84E-03 | 10 | P13765, P01106, Q13547, O00463, P07948, Q13761, P24522, P07766, P09693, P20963 | HLA-DOB, MYC, HDAC1, TRAF5, LYN, RUNX3, GADD45A, CD3E, CD3G, CD247 | More | | Pexidartinib | hsa05170 | Human immunodeficiency virus 1 infection | 5.51E-05 | 11 | P31751, P04049, P62873, P0DP23, P17252, Q14643, P01568, O60603, Q13315, P10415, Q9Y6Q5 | AKT2, RAF1, GNB1, CALM1, PRKCA, ITPR1, IFNA21, TLR2, ATM, BCL2, AP1M2 | More | | Pexidartinib | hsa05171 | Coronavirus disease - COVID-19 | 3.18E-03 | 7 | P01584, P62753, P36578, P62888, P61927, P61513, P62829 | IL1B, RPS6, RPL4, RPL30, RPL37, RPL37A, RPL23 | More | | Pexidartinib | hsa05200 | Pathways in cancer | 8.38E-03 | 13 | P42224, Q9UJU2, P17252, P14923, P10415, Q13489, P49767, Q12778, P31751, P25116, P62873, P0DP23, P01568 | STAT1, LEF1, PRKCA, JUP, BCL2, BIRC3, VEGFC, FOXO1, AKT2, F2R, GNB1, CALM1, IFNA21 | More | | Pexidartinib | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | Pexidartinib | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Pexidartinib | hsa05205 | Proteoglycans in cancer | 1.09E-02 | 6 | P04049, P14780, P01375, P23588, Q13635, P22694 | RAF1, MMP9, TNF, EIF4B, PTCH1, PRKACB | More | | Pexidartinib | hsa05206 | MicroRNAs in cancer | 3.15E-02 | 1 | P04049 | RAF1 | More | | Pexidartinib | hsa05210 | Colorectal cancer | 2.55E-03 | 3 | Q9UKG1, P04049, P37173 | APPL1, RAF1, TGFBR2 | More | | Pexidartinib | hsa05211 | Renal cell carcinoma | 5.09E-05 | 3 | Q13153, P31751, P04049 | PAK1, AKT2, RAF1 | More | | Pexidartinib | hsa05212 | Pancreatic cancer | 5.93E-04 | 4 | P31751, P04049, Q15311, P23458 | AKT2, RAF1, RALBP1, JAK1 | More | | Pexidartinib | hsa05213 | Endometrial cancer | 8.16E-04 | 2 | P31751, P04049 | AKT2, RAF1 | More | | Pexidartinib | hsa05214 | Glioma | 8.46E-06 | 3 | P0DP23, P04049, P31751 | CALM1, RAF1, AKT2 | More | | Pexidartinib | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P04049 | RAF1 | More | | Pexidartinib | hsa05218 | Melanoma | 4.47E-04 | 2 | P31751, P04049 | AKT2, RAF1 | More | | Pexidartinib | hsa05219 | Bladder cancer | 5.65E-03 | 3 | P14780, P04637, P04049 | MMP9, TP53, RAF1 | More | | Pexidartinib | hsa05220 | Chronic myeloid leukemia | 9.63E-04 | 2 | P31751, P04049 | AKT2, RAF1 | More | | Pexidartinib | hsa05221 | Acute myeloid leukemia | 8.16E-04 | 2 | P31751, P04049 | AKT2, RAF1 | More | | Pexidartinib | hsa05222 | Small cell lung cancer | 4.78E-02 | 1 | P31751 | AKT2 | More | | Pexidartinib | hsa05223 | Non-small cell lung cancer | 3.49E-04 | 2 | P31751, P04049 | AKT2, RAF1 | More | | Pexidartinib | hsa05224 | Breast cancer | 1.24E-02 | 5 | P04049, P49841, Q92837, P04637, P24522 | RAF1, GSK3B, FRAT1, TP53, GADD45A | More | | Pexidartinib | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P04049 | RAF1 | More | | Pexidartinib | hsa05226 | Gastric cancer | 6.81E-04 | 2 | P04049, P31751 | RAF1, AKT2 | More | | Pexidartinib | hsa05230 | Central carbon metabolism in cancer | 1.12E-03 | 2 | P04049, P31751 | RAF1, AKT2 | More | | Pexidartinib | hsa05231 | Choline metabolism in cancer | 4.08E-04 | 7 | P04049, P31751, Q9Y259, P19174, P49619, Q16760, O14986 | RAF1, AKT2, CHKB, PLCG1, DGKG, DGKD, PIP5K1B | More | | Pexidartinib | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.33E-07 | 12 | P42338, O95267, P19174, P07766, P20963, P09693, P06239, P04049, O60603, Q04759, Q16539, P01730 | PIK3CB, RASGRP1, PLCG1, CD3E, CD247, CD3G, LCK, RAF1, TLR2, PRKCQ, MAPK14, CD4 | More | | Pexidartinib | hsa05320 | Autoimmune thyroid disease | 1.27E-03 | 4 | P13765, P29965, P01568, P10747 | HLA-DOB, CD40LG, IFNA21, CD28 | More | | Pexidartinib | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | | Pexidartinib | hsa05322 | Systemic lupus erythematosus | 3.04E-07 | 13 | P08246, P08311, P09871, P10747, P13765, P29965, Q6FI13, Q93077, P62807, Q16778, O60814, P68431, P12814 | ELA2, CTSG, C1S, CD28, HLA-DOB, CD40LG, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, ACTN1 | More | | Pexidartinib | hsa05323 | Rheumatoid arthritis | 1.29E-02 | 4 | P13765, Q13488, P10747, O60603 | HLA-DOB, TCIRG1, CD28, TLR2 | More | | Pexidartinib | hsa05330 | Allograft rejection | 1.04E-03 | 5 | P13765, P29965, P48023, P10747, P01375 | HLA-DOB, CD40LG, FASLG, CD28, TNF | More | | Pexidartinib | hsa05332 | Graft-versus-host disease | 9.47E-05 | 5 | P13765, P48023, P01375, P26715, Q13241 | HLA-DOB, FASLG, TNF, KLRC1, KLRD1 | More | | Pexidartinib | hsa05340 | Primary immunodeficiency | 2.19E-02 | 4 | P01730, P01732, P07766, P06239 | CD4, CD8A, CD3E, LCK | More | | Pexidartinib | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.48E-02 | 1 | P54284 | CACNB3 | More | | Pexidartinib | hsa05414 | Dilated cardiomyopathy | 4.55E-02 | 2 | P54284, P26678 | CACNB3, PLN | More | | Pexidartinib | hsa05415 | Diabetic cardiomyopathy | 2.54E-04 | 9 | P17252, P30405, P14598, Q15080, Q16718, O14521, Q16539, P49841, P37173 | PRKCA, PPIF, NCF1, NCF4, NDUFA5, SDHD, MAPK14, GSK3B, TGFBR2 | More | | Pexidartinib | hsa05416 | Viral myocarditis | 2.62E-02 | 3 | P13765, P29965, P10747 | HLA-DOB, CD40LG, CD28 | More | | Pexidartinib | hsa05418 | Fluid shear stress and atherosclerosis | 1.27E-05 | 10 | Q16539, P31751, Q14145, P10599, P14780, P01375, P04637, P14778, P27930, P0DP23 | MAPK14, AKT2, KEAP1, TXN, MMP9, TNF, TP53, IL1R1, IL1R2, CALM1 | More | | |